Ellis MK et al. Inhibition of 4-Hydroxyphenylpyruvate Dioxygenase by 2-(2-Nitro-4-trifluoromethylbenzoyl)-cyclohexane-1,3-dione and 2-(2-Chloro-4-methanesulfonylbenzoyl)-cyclohexane-1,3-dione. Toxicol Appl Pharmacol1995; 133: 12-19.
2.
Lindstedt S. et al. Treatment of hereditary tyrosinaemia type 1 by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet1992; 340: 813-817.
3.
Weinberg AG, Mize CE, Worthen HGThe occurrence of hepatoma in the chronic form of hereditary tyrosinemia . J Pediatr1976; 88: 434-438.
4.
Mitchell GA et al. Neurologic crises in hereditary tyrosinemia. N Engl J Med1990; 322: 432-437.
5.
Holme E., Lindstedt S., Lock EATreatment of Tyrosinemia Type I with and Enzyme Inhibitor (NTBC). InternatJ Pediatr1995; 10: 41-43.
6.
Grompe M., Lindstedt S., Al-Dhalimy M., Kennaway NG, Papaconstantinou J., Torred-Ramos CA, Ou C-N., Finegold M.Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genet1995; 10: 453-460.
